[1. World Health Organization [Internet]. Geneva: Global status report on noncommunicable diseases 2010. [updated 2011 Apr; cited 2014 Dec 9]. Available from: http://www.who.int/nmh/publications/ncd_report2010/en/.]Search in Google Scholar
[2. Gorbas IM, Barna OM, Sakalosh VY, Bakumenko MA. [Estimated prevalence and control of risk factors for cardiovascular disease in the population and physicians]. Liky Ukrainy. 2010;(1):24-6. Ukrainian.]Search in Google Scholar
[3. Gaydaev YO, Kornatchkyi VM. [Health problems and directions of its improvement in modern conditions]. Ukr. Kardiol. J. 2007;(5):7. Ukrainian.]Search in Google Scholar
[4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 2006,3(11):e 442.10.1371/journal.pmed.0030442166460117132052]Search in Google Scholar
[5. Spagnoli LG, Bonnano E., Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med. 200748(11):1800-15.10.2967/jnumed.107.03866117942804]Search in Google Scholar
[6. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr rev. 2007;65(12 Pt 2):140-6.10.1301/nr.2007.dec.S140-S146]Search in Google Scholar
[7. Shan P.K. Molecular mechanisms of plaque instability. Curr Opin Lipidol. 2007;18(5):492-9.10.1097/MOL.0b013e3282efa32617885418]Search in Google Scholar
[8. Sumagin R, Sarelius I. A role for ICAM−1 in maintenance of leucocite−endothelial cell rolling interactions in inflammed arteries. Am J Physiol Heart Circ Physiol. 2007;293(5):H2786-98.10.1152/ajpheart.00720.200717704289]Search in Google Scholar
[9. Pereira IA, Borba EF. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly. 2008;138(37-38):534-9.]Search in Google Scholar
[10. Stancu CS, Toma L, Sima AV. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Res. 2012;349(2):433-46.10.1007/s00441-012-1437-122592627]Search in Google Scholar
[11. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-41.10.1038/35025203282622211001066]Search in Google Scholar
[12. Etsuo N. Do free radicals play causal role in atherosclerosis? Low density lipoprotein oxidation and vitamin E revisited. J Clin Biochem Nutr. 2011;48(1):3-7.]Search in Google Scholar
[13. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation. 1997;96(10): 3264-5.]Search in Google Scholar
[14. Watson C, Nicholas J. ALP. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci. 2008;114:509-31.10.1042/CS2007029818336368]Search in Google Scholar
[15. Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150(5):1785-90.]Search in Google Scholar
[16. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol. 1969;56(1):111-28.]Search in Google Scholar
[17. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr. 2000;130(2S Suppl):369S-72S.10.1093/jn/130.2.369S10721909]Search in Google Scholar
[18. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11 Suppl 1:S56-64.10.1038/sj.cdd.440145115243582]Search in Google Scholar
[19. AbdulleAM, Pathan JY, Moussa N, Gariballa S. Association between homocysteine and endothelial dysfunction markers in stroke disease. Nutr Neurosci. 2010;13(1):2-6.10.1179/147683010X12611460763562]Search in Google Scholar
[20. Verhoef P, Stampfer MJ. Prospective studies of homocysteine and cardiovascular disease. Nutr Rev. 1995;53910):283-8.10.1111/j.1753-4887.1995.tb01478.x]Search in Google Scholar
[21. Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med. 1995;33295):328-9.10.1056/NEJM199502023320511]Search in Google Scholar
[22. Graham M, Daly L, Refsum H, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA. 1997;277(22):1775-81.10.1001/jama.1997.03540460039030]Search in Google Scholar
[23. Mayer E, Jacobsen D, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27(3):517-27.10.1016/0735-1097(95)00508-0]Search in Google Scholar
[24. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354(9176):407-13.10.1016/S0140-6736(98)11058-9]Search in Google Scholar
[25. Burtina IY. [Effect of the composite preparation Cardonat on plasma homocysteine level in patients with coronary artery disease]. Ukrain Med. Chasopis. 2005;1(45): 45-8. Russian.]Search in Google Scholar
[26. Blacher J, Benetos A, Kirzin J, Malmejac A, Guize L, Safar ME. Relation of plasma homocysteine to cerebrovascular mortality in a French population. Am J Cardiol. 2002;90(6):591-5.10.1016/S0002-9149(02)02561-4]Search in Google Scholar
[27. Ciaccio M, Bivona G, Bellia C. Therapeutical approach to plasma homocysteine and cardiovascular risk reduction. Ther Clin Risk Manag. 2008;4(1):219-24.10.2147/TCRM.S1807250365718728711]Search in Google Scholar
[28. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk. J Appl Genet. 2008;49(3):267-82.10.1007/BF0319562418670064]Search in Google Scholar
[29. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003;60(6):618-26.10.1001/archpsyc.60.6.61812796225]Search in Google Scholar
[30. Bailey LB, Gregory JF 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr. 1999;129(5):919-22.10.1093/jn/129.5.91910222379]Search in Google Scholar
[31. Martin YN, Salavaggione OE, Eckloff BW, Wieben ED, Schaid DJ, Weinshilboum RM. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenetics and Genomics. 2006;16(4):265-77.10.1097/01.fpc.0000194423.20393.0816538173]Search in Google Scholar
[32. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. Consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins incardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003;41:1392-403.10.1515/CCLM.2003.21414656016]Search in Google Scholar
[33. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337(4):230-36.10.1056/NEJM1997072433704039227928]Search in Google Scholar
[34. Oudi ME, Aouni Z, Mazigh C, Khochkar R, Gazoueni E, Haouela H, et al. Homocysteine and markers of inflammation in acute coronary syndrome. Exp Clin Cardiol. 2010;15(2):e25-28.]Search in Google Scholar
[35. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drug Ther. 2002;16(5):391-9.10.1023/A:1022130217463]Search in Google Scholar
[36. Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, Gerrits WB, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate-reductase (MTHFR) and inherited thrombophilic factors in venous thromboembolism. Thromb Haemost. 2002;88(5):723-8.10.1055/s-0037-1613292]Search in Google Scholar
[37. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3(2):292-9.10.1111/j.1538-7836.2005.01141.x15670035]Search in Google Scholar
[38. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood. 2004;104:3046-51.10.1182/blood-2004-03-089715226189]Search in Google Scholar
[39. Brattström L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98(23):2520-6.10.1161/01.CIR.98.23.25209843457]Search in Google Scholar
[40. Martin YN, Salavaggione OE, Eckloff BW, Wieben ED, Schaid DJ, Weinshilboum RM. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics. 2006;16:265-77.10.1097/01.fpc.0000194423.20393.08]Search in Google Scholar
[41. Xu H, Liu C, Wang Q. Plaque image characteristics, hyperhomocysteinemia, and gene polymorphism of homocysteine metabolism-related enzyme (MTHFR C677T) in acute coronary syndrome. Cell Biochem Biophys. 2013;66(2): P. 403-7.10.1007/s12013-012-9483-623314883]Search in Google Scholar